500
Participants
Start Date
September 1, 2017
Primary Completion Date
September 1, 2024
Study Completion Date
September 1, 2024
Incretin Effect
The patients will receive incretins therapy.
Cardiac Resynchronization therapy defibrillator device
The patients will receive a Cardiac Resynchronization therapy defibrillator device
SGLT-2 inhibitor
The patients will receive SGLT2i therapy.
Raffaele Marfella, Naples
University of Campania Luigi Vanvitelli
OTHER